Browsing by Author "Sarialioglu, F."
Now showing 1 - 15 of 15
- Results Per Page
- Sort Options
Item Beta Blocker Treatment in Hemangiomas: Experience in 344 Cases in A Single Institute(2014) Yazici, N.; Sarialioglu, F.; Erbay, A.; Erdogan, I.; Misirlioglu, P. Kiper; https://orcid.org/0000-0002-8257-810X; https://orcid.org/0000-0001-6887-3033; AAM-5138-2021; AAL-7766-2021; ABB-2220-2021Item Central Nervous System Metastases in Neuroblastoma: Results of Turkish Pediatric Oncology Group Neuroblastoma 2009 (TPOG-NB-2009) Protocol(2018) Cecen, E.; Ince, D.; Sevinir, B.; Cakir, F. B.; Kurucu, N.; Guler, E.; Vural, S.; Koksal, Y.; Oniz, H.; Oguz, A.; Sarialioglu, F.; Olgun, N.; https://orcid.org/0000-0002-8257-810X; AAL-7766-2021Item Cytogenetic Features of Acute Leukemia Patients Treated at a Single Center at East Mediterenian and South Region of Turkey(2019) Aktekin, E.; Yazici, N.; Erbay, A.; Celik, Z. Yilmaz; Kozanoglu, I.; Sarialioglu, F.Item High Survival Rates in Hodgkin's Lymphoma in a Developing Country: No Mortality in Protocol Patients without A CO-MORBID Problem(2017) Yazici, N.; Sarialioglu, F.; Onal, H. C.; Erbay, A.; Hasbay, B.; Demir, S.; Temiz, A.; Nursal, G. N.; 0000-0002-8257-810X; 0000-0002-4209-9075; 0000-0002-5302-4386; AAM-5138-2021; AAL-7766-2021; AAK-9310-2021; R-3735-2016Item Intestinal Mucor Infection in a Patient with Non-Hodgkin's Lymphoma During Induction Chemotherapy(2017) Erbay, A.; Sarialioglu, F.; Yazici, N.; Ezer, S.; Hasbay, B.; 0000-0002-8257-810X; AAL-7766-2021; AAM-5138-2021; AAJ-9529-2021Item Langerhans Cell Histiocytosis: A Single Center Experience(2019) Ince, D.; Baysal, B.; Kizmazoglu, D.; Akyol, S.; Oksel, B.; Ozer, E.; Guleryuz, H.; Havitcioglu, H.; Mutafoglu, K.; Sarialioglu, F.; Cevik, N.; Olgun, H. NurItem Neuroblastoma and Opsomyoclonus Syndrome: Experience of 6 Cases at a Single Center(2019) Yazici, N.; Gezer, H. O.; Aktekin, E.; Saygi, S.; Erol, I.; Erbay, A.; Sarialioglu, F.; J-3197-2013Item A New Perspective for Infantile Hepatic Hemangioma in the Age of Proranolol(2016) Sarialioglu, F.; Yazici, N.; Boyvat, F.; Demir, S.; Ozcay, F.; Uslu, N.; 0000-0002-8257-810X; 0000-0002-5214-516X; 0000-0002-4209-9075; AAL-7766-2021; AAM-5138-2021; ABG-5684-2020; AAK-9310-2021; F-4230-2011Item The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?(2020) Belen-Apak, F. B.; Sarialioglu, F.; 0000-0002-9278-6703; 0000-0002-8257-810X; 32335456; AAJ-8171-2021; AAL-7766-2021Currently, our world is facing the 2019 Novel Coronavirus (COVID-19) outbreak and tremendous efforts are made for developing drugs to treat and vaccines to prevent the disease. At present, there is no specific antiviral drug or vaccine for COVID-19. The pathogenic infectivity of the virus requires the S1 subunit of the spike (S) protein to bind the host cell receptor, angiontensin converting enzyme (ACE2). While the binding to host cell receptor is the first step of infection, the entrance of the virus into the cell needs the cleavage of S1-S2 subunits to expose S2 for fusion to cell membrane via host proteases including cathepsins, cell surface transmembrane protease/serine (TMPRSS) proteases, furin, trypsin and factor Xa. Previous in vitro studies have shown that factor Xa inhibition can decrease viral infectivity. We suppose that host cell proteases including furin (as expressed highly in lungs), factor Xa and cathepsin are possible targets to decrease viral burden, therefore unfractioned heparin and low molecular weight heparin-LMWH (specifically dalteparin and tinzaparin for their anti inflammatory action) can be potential inhibitors of multiple endoproteases involved in virus infectivity. Our hypothesis needs to be tested in in vitro and clinical studies, however as we are in an urgent situation as the burden of SARS-CoV2 is increasing all around the world, we recommend the usage of unfractioned heparin or LMWH in intensive care unit (ICU) and non-ICU hospitalized patients with the risk-benefit judgement of the clinician. Whether our hypothesis is clinically applicable and successful in decreasing viral infection will be evaluated for further stuItem Paediatric Hodgkin Lymphoma: A Single Center Experience from the West Part of Turkey(2016) Mutafoglu, K.; Ince, D.; Demiral, A.; Yenigurbuz, F.; Kizmazoglu, D.; Armagan, C.; Ozer, E.; Guleryuz, H.; Sarialioglu, F.; Olgun, N.; 0000-0002-8257-810X; AAL-7766-2021Item Posttransplantation Lymphoproliferative Disease in Children with Liver Transplantation: Baskent University Experience(2016) Sarialioglu, F.; Ozcay, F.; Boyvat, F.; Yazici, N.; Ozdemir, H.; Coskun, M.; Aydin, E.; Haberal, M.; 0000-0002-5214-516X; 0000-0002-8257-810X; 0000-0002-3462-7632; 0000-0001-6864-7378; 0000-0001-5630-022X; ABG-5684-2020; F-4230-2011; AAL-7766-2021; AAM-5138-2021; AAJ-8097-2021; AAJ-2379-2021; AAM-4120-2021Item Propranolol in Tumors Except Infantile Hemangiomas: Presentation of Four Cases(2014) Sarialioglu, F.; Yazici, N.; Erbay, A.; Demir, S.; Alkan, O.; Kocer, N. E.; Uckan, S.; https://orcid.org/0000-0002-8257-810X; https://orcid.org/0000-0002-4209-9075; https://orcid.org/0000-0001-7526-3460; https://orcid.org/0000-0002-5943-9283; AAL-7766-2021; AAK-9310-2021; AAM-4169-2021; AAM-5436-2021Item Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy(2020) Belen-Apak, F. Burcu; Sarialioglu, F.; 0000-0002-8257-810X; 0000-0002-9278-6703; 32372336; AAL-7766-2021; AAJ-8171-2021Item A Single Center Experience of Pediatric Hodgkin Lymphoma(2018) Ince, D.; Erdem, M.; Kizmazoglu, D.; Cecen, E.; Demiral, A.; Cetingoz, R.; Ozer, E.; Guleryuz, H.; Ozdogan, O.; Olguner, M.; Erdag, T.; Mutafoglu, K.; Sarialioglu, F.; Olgun, N.; https://orcid.org/0000-0002-8257-810X; AAL-7766-2021Item Stage IV Neuroblastoma: Single Center Experience: Treatment Consolidation(2019) Yazici, N.; Sarialioglu, F.; Temiz, A.; Cem, H. Onal; Reyhan, M.; Demir, S.; Hasbay, B.; Aktekin, E.; Erbay, A.